A phase II randomized trial of doxorubicin (DXR) and gemcitabine (GMZ) administered in patients with metastatic breast cancer (MBC)

被引：0
|
作者：
A Bensalem
K Bouzid
机构：
[1] Chu Dr Benbardis,Medical Oncology
来源：
Breast Cancer Research | / 7卷
关键词：
Breast Cancer; Doxorubicin; Neutropenia; Gemcitabine; Partial Response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Phase II study of gemcitabine in patients with metastatic breast cancer
    Blackstein, M
    Vogel, CL
    Ambinder, R
    Cowan, J
    Pearce, P
    Iglesias, J
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 664 - 664
  • [22] Randomized, phase II trial comparing continuous versus intermittent capecitabine monotherapy for metastatic breast cancer (MBC)
    Martin, M.
    Calvo, L.
    Martinez, N.
    Ramos, M.
    Munoz, M.
    Zamora, P.
    Hernando, B.
    Casado, A.
    Garcia-Saenz, J. A.
    Puente, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [23] Phase II randomized study of capecitabine (C) administered as continuous versus standard (cyclic) treatment in patients (PTS) with metastatic breast cancer (MBC)
    Martin, Miguel
    Casado, A.
    Garcia-Saenz, J. A.
    Calvo, Lourdes
    Constenla, Manuel
    Diaz-Rubio, E.
    ANNALS OF ONCOLOGY, 2006, 17 : 74 - 74
  • [24] PHASE II TRIAL WITH RFS2000 IN PATIENTS (PTS) WITH ADVANCED AND/OR METASTATIC BREAST CANCER (MBC)
    Sorio, R.
    Chollet, P.
    Caponigro, F.
    Carteni, G.
    Sealone, S.
    Crivellari, D.
    Magri, M. D.
    Adank, S. J.
    Veronesi, A.
    ANNALS OF ONCOLOGY, 2004, 15 : 18 - 18
  • [25] Gemcitabine (G) and cisplatin (C) as first-line treatment of metastatic breast cancer (MBC): Results of phase II trial
    Karthaus, Meinolf
    Poddubnaya, Irina
    Churilova, L.
    Khazanov, R.
    Veremeychuk, T.
    Rumyantzeva, E.
    Garin, M.
    Brichkova, O.
    Heinrich, Bernhard
    Heinemann, Volker
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] Gemcitabine as first-line therapy in patients with metastatic breast cancer: A phase II trial
    Blackstein, M
    Vogel, CL
    Ambinder, R
    Cowan, J
    Iglesias, J
    Melemed, A
    ONCOLOGY, 2002, 62 (01) : 2 - 8
  • [27] A phase II trial of docetaxel in patients (PTS) with anthracycline resistant (AR) metastatic breast cancer (MBC)
    Guastalla, JP
    Bonneterre, J
    Fumoleau, P
    Piccart, M
    Tubiana, M
    Chevallier, B
    Nieamann, C
    Alakl, M
    Nichol, A
    Riva, A
    Marty, M
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 348 - 348
  • [28] A phase II trial of a combination of pemetrexed and gemcitabine in patients with metastatic breast cancer: an NCCTG study
    Ma, CX
    Steen, P
    Rowland, KM
    Niedringhaus, RD
    Fitch, TR
    Kugler, JW
    Hillman, DW
    Perez, EA
    Ingle, JN
    Adjei, AA
    ANNALS OF ONCOLOGY, 2006, 17 (02) : 226 - 231
  • [29] PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) AND GEMCITABINE (G) COMBINATION IN METASTATIC BREAST CANCER (MBC) PATIENTS: ACTIVITY AND TOXICITY
    Fabi, A.
    Papaldo, P.
    Ciccarese, M.
    Salesi, N.
    Lorusso, V.
    Ferretti, G.
    Di Cocco, B.
    Carlini, P.
    Cecere, F.
    Pellicciotta, M.
    Morace, N.
    Cognetti, F.
    ANNALS OF ONCOLOGY, 2004, 15 : 24 - 24
  • [30] A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer
    Perez, EA
    Geeraerts, L
    Suman, VJ
    Adjei, AA
    Baron, AT
    Hatfield, AK
    Maihle, N
    Michalak, JC
    Kuross, SA
    Kugler, JW
    Lafky, JM
    Ingle, JN
    ANNALS OF ONCOLOGY, 2002, 13 (08) : 1225 - 1235
12345